CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
CollPlant Biotechnologies (CLGN) and Stratasys (SSYS) have initiated a pre-clinical study for 3D-printed regenerative breast implants. The 200cc commercial-sized implants, made using CollPlant's rhCollagen-based bioinks and printed on a Stratasys Origin® printer, aim to promote natural breast tissue growth and completely degrade over time. This innovation targets the $3 billion breast implant market, offering a potential alternative to traditional silicone implants and autologous fat transfer procedures.
The collaboration focuses on developing a bioprinting solution and scaling up the fabrication process. Initial results from the study are expected in the first half of 2025. Previous pre-clinical studies have shown promising results, including neovascularization and tissue regeneration without adverse reactions.
CollPlant Biotechnologies (CLGN) e Stratasys (SSYS) hanno avviato uno studio preclinico per protesi mammarie rigenerative stampate in 3D. Queste protesi di dimensioni commerciali di 200cc, realizzate con i bioinchiostri a base di rhCollagen di CollPlant e stampate su una stampante Stratasys Origin®, mirano a promuovere la crescita naturale del tessuto mammario e a degradarsi completamente nel tempo. Questa innovazione si rivolge al mercato delle protesi mammarie da 3 miliardi di dollari, offrendo una potenziale alternativa alle tradizionali protesi in silicone e alle procedure di trasferimento di grasso autologo.
La collaborazione si concentra sullo sviluppo di una soluzione di biostampa e sulla scalabilità del processo di fabbricazione. I risultati iniziali dello studio sono attesi nella prima metà del 2025. Studi preclinici precedenti hanno mostrato risultati promettenti, inclusa la neovascolarizzazione e la rigenerazione dei tessuti senza reazioni avverse.
CollPlant Biotechologies (CLGN) y Stratasys (SSYS) han iniciado un estudio preclínico para implantes mamarios regenerativos impresos en 3D. Los implantes de tamaño comercial de 200cc, fabricados con bioinks a base de rhCollagen de CollPlant y impresos en una impresora Stratasys Origin®, tienen como objetivo promover el crecimiento natural del tejido mamario y degradarse completamente con el tiempo. Esta innovación apunta al mercado de implantes mamarios de 3 mil millones de dólares, ofreciendo una alternativa potencial a los implantes de silicona tradicionales y a los procedimientos de transferencia de grasa autóloga.
La colaboración se centra en desarrollar una solución de bioprinters y en escalar el proceso de fabricación. Se esperan los resultados iniciales del estudio en la primera mitad de 2025. Estudios preclínicos anteriores han mostrado resultados prometedores, incluyendo la neovascularización y la regeneración de tejidos sin reacciones adversas.
CollPlant Biotechnologies (CLGN)와 Stratasys (SSYS)는 3D 프린팅된 재생 유방 임플란트에 대한 전임상 연구를 시작했습니다. CollPlant의 rhCollagen 기반 바이오 잉크로 제작된 상업용 크기 200cc 임플란트는 Stratasys Origin® 프린터에서 인쇄되어 자연 유방 조직 성장을 촉진하고 시간이 지남에 따라 완전히 분해될 것을 목표로 하고 있습니다. 이 혁신은 30억 달러 규모의 유방 임플란트 시장을 겨냥하며, 전통적인 실리콘 임플란트 및 자가 지방 이식 절차에 대한 잠재적인 대안을 제공합니다.
이번 협력은 바이오프린팅 솔루션 개발과 제작 과정의 규모 확대에 중점을 두고 있습니다. 연구의 초기 결과는 2025년 상반기에 예상됩니다. 이전 전임상 연구에서는 신생혈관형성과 조직 재생이 부작용 없이 이루어졌다는 유망한 결과를 보여주었습니다.
CollPlant Biotechnologies (CLGN) et Stratasys (SSYS) ont lancé une étude préclinique pour des implants mammaires régénératifs imprimés en 3D. Ces implants de taille commerciale de 200cc, fabriqués avec des bioinks à base de rhCollagen de CollPlant et imprimés sur une imprimante Stratasys Origin®, visent à promouvoir la croissance naturelle du tissu mammaire et à se dégrader complètement au fil du temps. Cette innovation cible le marché des implants mammaires de 3 milliards de dollars, offrant une alternative potentielle aux implants en silicone traditionnels et aux procédures de transfert de graisse autologue.
La collaboration se concentre sur le développement d'une solution de bioprinting et sur l'augmentation de l'échelle du processus de fabrication. Les premiers résultats de l'étude sont attendus dans la première moitié de 2025. Des études précliniques antérieures ont montré des résultats prometteurs, y compris la néovascularisation et la régénération des tissus sans réactions indésirables.
CollPlant Biotechnologies (CLGN) und Stratasys (SSYS) haben eine klinische Vorstudie für 3D-gedruckte regenerative Brustimplantate eingeleitet. Die kommerziell verfügbaren Implantate mit 200cc, hergestellt mit den rhCollagen-basierten Bio-Tinten von CollPlant und auf einem Stratasys Origin®-Drucker gedruckt, zielen darauf ab, das natürliche Wachstum des Brustgewebes zu fördern und sich im Laufe der Zeit vollständig abzubauen. Diese Innovation richtet sich an den 3-Milliarden-Dollar-Markt für Brustimplantate und bietet eine potenzielle Alternative zu herkömmlichen Silikonimplantaten und autologen Fetttransfervorgängen.
Die Zusammenarbeit konzentriert sich auf die Entwicklung einer Bioprinting-Lösung und die Hochskalierung des Herstellungsprozesses. Erste Ergebnisse der Studie werden in der ersten Hälfte von 2025 erwartet. Frühere klinische Vorstudien haben vielversprechende Ergebnisse gezeigt, darunter Neovaskularisation und Geweberegeneration ohne unerwünschte Reaktionen.
- Initiation of pre-clinical study for 200cc commercial-sized regenerative breast implants
- Successful 3D printing of implants using CollPlant's rhCollagen-based bioinks on Stratasys Origin® printer
- Targeting a $3 billion addressable breast implant market
- Previous pre-clinical studies showed positive results with neovascularization and tissue regeneration
- Initial results from the new study not expected until first half of 2025
- Product still in pre-clinical stage, indicating a long path to potential commercialization
Insights
This pre-clinical study marks a significant milestone in regenerative medicine for breast implants. The collaboration between CollPlant and Stratasys to develop 200cc commercial-sized regenerative implants using 3D printing technology is truly innovative. Key points to consider:
- The implants are designed to promote natural breast tissue growth and completely degrade over time, potentially revolutionizing both reconstructive and aesthetic procedures.
- Previous pre-clinical studies showed promising results, including neovascularization and progressing tissue ingrowth without adverse reactions.
- If successful, this technology could address the
$3 billion breast implant market, offering a safer alternative to silicone implants.
However, investors should note that initial results are not expected until H1 2025, indicating a long path to potential commercialization.
CollPlant's rhCollagen-based bioinks combined with Stratasys' 3D printing expertise represent a potential paradigm shift in breast implant technology. This collaboration leverages cutting-edge bioprinting to address longstanding issues in the field:
- The regenerative aspect could significantly reduce complications associated with traditional silicone implants.
- Successful commercialization could disrupt the
$3 billion global breast implant market. - The technology's potential extends beyond breast implants to other regenerative medicine applications.
However, investors should exercise caution. The road from pre-clinical studies to FDA approval is long and uncertain, with many potential hurdles. The 2025 timeline for initial results suggests a considerable wait before any potential revenue impact.
While the potential market opportunity is significant, investors should temper short-term expectations:
- The
$3 billion addressable market is attractive, but penetration will take time and face regulatory hurdles. - R&D costs are likely to be substantial over the next few years, potentially impacting near-term financials.
- Commercialization, if successful, is likely several years away, given the 2025 timeline for initial results.
However, long-term potential is noteworthy. Success could position CollPlant and Stratasys as leaders in regenerative medicine, potentially opening doors to other lucrative applications. Investors should view this as a high-risk, high-reward long-term play, with careful attention to upcoming milestones and regulatory progress.
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested
Technology innovation addresses a
Study to focus on ability of implants to grow natural breast tissue and completely degrade over time
REHOVOT,
The collaboration between CollPlant and Stratasys is currently focused on the development of a bioprinting solution for CollPlant's breast implants, in addition to finding solutions to scale-up the implant's fabrication process. The study is intended to test the ability of the implants to promote the growth of natural breast tissue and completely degrade over time.
CollPlant's novel breast implants have been designed to regenerate an individual's natural breast tissue without eliciting an immune response, and could provide a revolutionary alternative for both reconstructive and aesthetic procedures, which represents a significant portion of the overall
"This pre-clinical study marks a significant step forward in our effort to provide patients with care using regenerative medicine instead of traditional implants," said Stratasys CEO Dr. Yoav Zeif. "CollPlant's work is truly inspiring, and our collaboration exemplifies how Stratasys partners with customers to push the timeline and the boundaries of innovation. Together, we are driven by a shared mission to challenge the status quo and find new ways to improve lives and advance healthcare."
Yehiel Tal, CEO of CollPlant, commented, "We are extremely happy about the progress we've made with our breast implants program, and with Stratasys' successful achievement to develop a printer that enables us to print a commercial-size implant with high resolution and optimal physical properties. The combined pioneering technologies of both companies is expected to streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants. We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat transfer, thereby significantly improving patient outcomes."
Stratasys is a leader in polymer 3D printing solutions and CollPlant is a pioneering regenerative and aesthetics medicine company developing innovative technologies and products based on its rhCollagen for tissue regeneration and organ manufacturing.
Since announcing the collaboration in April of 2023, Stratasys has adapted the Origin printer to print the regenerative implants, and CollPlant successfully managed to 3D-print them at 200ccs. CollPlant is expecting to have initial results from the study in the first half of 2025.
Currently the global breast implant market is estimated to be
Earlier this year, CollPlant announced additional positive data from its previous pre-clinical studies that are currently underway which showed evidence of well-developed connective tissue containing blood vessels (i.e., neovascularization) within the implant. Progressing tissue ingrowth inside the implant was also observed confirming tissue regeneration. An initial biodegradation process was noticed, while the original structure of the 3D breast implant was preserved. No adverse tissue reaction was present, confirming the safety profile of this novel implant in development.
1 https://www.thebrainyinsights.com/report/breast-implants-market-14142
2 ISAPS International Survey on Aesthetic/Cosmetic Procedures, 2021
About Stratasys
Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products, healthcare, fashion and education. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world's leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.
To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, X/Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including the Company's websites, to share material, non-public information pursuant to the SEC's Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.
Stratasys and Origin One are trademarks or registered trademarks and the Stratasys signet is a trademark of Stratasys Ltd. and/or its subsidiaries or affiliates. All other trademarks are the property of their respective owners.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. CollPlant's products are based on its recombinant human collagen produced with its proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021 CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information, visit http://www.collplant.com
Safe Harbor for Forward-Looking Statements
This joint press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Stratasys' and/or CollPlant's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Stratasys and/or CollPlant intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of the companies' respective management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements included in this press release include, but are not limited to, statements regarding the following: the companies' ability to develop a 3D bioprinter that is based on Stratasys' P3™ 3D printing technology and can be used with CollPlant's rhCollagen-based BioInk; CollPlant's expectations regarding the cost and timing of commencing or concluding pre-clinical and clinical trials, with respect to breast implants, tissues and organs based on its rhCollagen based bioinks and other products for medical aesthetics; CollPlant's ability to obtain favorable pre-clinical and clinical trial results with respect to the foregoing trials; regulatory action with respect to rhCollagen based bioinks and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the companies' combined 3D bioprinter and/or future potential collaborative products involving Stratasys' P3™ 3D printing technology and/or CollPlant's rhCollagen based bioinks and/or CollPlant's regenerative breast implants and/or other medical aesthetics products; the companies' ability to establish sales and marketing capabilities or enter into agreements with third parties, including third party distributors and resellers; and the companies' ability to establish and maintain strategic partnerships and other corporate collaborations. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Stratasys' or CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: CollPlant's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the companies' reliance on third parties to conduct some or all aspects of the development or manufacturing of their products; the scope of protection the companies are able to establish and maintain for their respective and joint intellectual property rights and the companies' ability to operate their respective businesses and their joint collaboration without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the companies operate, including, with respect to the ongoing war in
Photo -https://mma.prnewswire.com/media/2484562/CollPlant_Stratasys_Origin.jpg
Logo - https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
Contacts:
Media:
Erik Snider, Stratasys Corporate, Global Public Relations
+972 74 745 6053
Chris Reese, Stratasys Corporate, Americas Public Relations
+1 651 357 0877
Investor Relations:
Yonah Lloyd, CCO & VP Investor Relations
+972 74 745 4919
CollPlant
Eran Rotem, Deputy CEO & CFO
Eran@CollPlant.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-and-stratasys-announce-pre-clinical-study-for-regenerative-commercial-sized-breast-implants-302225181.html
SOURCE CollPlant
FAQ
What is the purpose of CollPlant and Stratasys' pre-clinical study for breast implants?
What is the size of the breast implants being tested in CollPlant's (CLGN) pre-clinical study?
When are the initial results expected from CollPlant's (CLGN) breast implant pre-clinical study?
What is the estimated size of the global breast implant market that CollPlant (CLGN) is targeting?
